エスケタミンの世界市場レポート 2025

エスケタミン市場規模は、今後数年で急成長が見込まれます。2029年の年間平均成長率（CAGR）は11.0％で、23億1,000万米ドルに成長します。予測期間中の成長は、治療抵抗性うつ病の有病率の上昇、研究開発プログラムへの投資の増加、スマートヘルスケアインフラへの需要、遠隔医療サービスの採用拡大、効果的な治療法としてのエスケタミンの受け入れ拡大に起因しています。この期間に予想される主な動向には、バイオテクノロジー企業とメンタルヘルス機関の提携、ヘルスケアアプリケーションにおけるロボット工学の利用、個別化医療戦略、センサーベースのデバイスの台頭、併用療法の可能性などがあります。

治療抵抗性うつ病（TRD）の有病率の増加が、今後数年間のエスケタミン市場の拡大を牽引すると予想されます。TRDとは、少なくとも2種類の抗うつ薬を適切な用量で十分な期間試しても改善しないうつ病を指します。治療抵抗性うつ病の増加は、従来の抗うつ薬の効果が限定的であり、うつ病エピソードの長期化や再発につながることが主な原因です。エスケタミンは、NMDA受容体を標的とする速効性メカニズムを提供することにより、TRDに対する有望な解決策を提供し、従来の抗うつ薬に反応しない患者に救済を提供します。例えば、2023年9月、米国国立精神衛生研究所（NIMH）は、米国の大うつ病性障害患者の約30％が標準治療に抵抗性を示すと報告しました。その結果、治療抵抗性うつ病の発生率の増加がエスケタミン市場の成長に拍車をかけています。

エスケタミンが治療抵抗性うつ病の単剤療法として承認されたことは、TRD治療における画期的な出来事です。エスケタミン市場の主要企業は、複数の治療法を組み合わせるのではなく、単一の薬剤で病態を管理する単剤療法など、先進的なソリューションの開発に注力しています。2025年1月、米国の製薬会社ジョンソン・エンド・ジョンソンは、米国食品医薬品局（FDA）が治療抵抗性うつ病（TRD）の成人患者に対する最初で唯一の単剤療法としてSPRAVATO（エスケタミン）を承認したと発表しました。臨床試験データに裏付けされた今回の承認は、SPRAVATOが24時間以内に顕著な改善を示し、抑うつ症状を速やかに緩和できることを示しています。この画期的な新薬は、従来の抗うつ薬に反応しない30％の患者にとって重要な選択肢となり、追加の内服薬を必要としないです。SPRAVATOの安全性プロファイルは良好であるが、潜在的な副作用を管理するためにリスク評価緩和戦略（REMS）の下で投与されます。このマイルストーンは、TRD治療における大きな進歩であり、患者の転帰改善への新たな希望をもたらすものです。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- 金利、インフレ、地政学、貿易戦争と関税、そしてコロナ禍と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界エスケタミンPESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界のエスケタミン市場：成長率分析
• 世界のエスケタミン市場の実績：規模と成長, 2019-2024
• 世界のエスケタミン市場の予測：規模と成長, 2024-2029, 2034F
• 世界エスケタミン総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界のエスケタミン市場：タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 経口薬
• 注射
• 鼻スプレー
• その他のタイプ
• 世界のエスケタミン市場：適応症別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 大うつ病性障害
• 慢性疼痛
• 心的外傷後ストレス障害
• 不安障害
• 世界のエスケタミン市場患者タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 成人患者
• 小児患者
• 高齢患者
• 世界のエスケタミン市場：用途別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 全身麻酔
• 治療抵抗性うつ病
• 世界のエスケタミン市場：流通チャネル別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院薬局
• オンライン薬局
• 小売薬局
• 世界のエスケタミン市場経口薬の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 即放錠
• 徐放錠
• 舌下錠
• 世界のエスケタミン市場、注射のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 静脈注射
• 筋肉内注射
• 皮下注射
• 世界のエスケタミン市場、鼻スプレーの種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 処方鼻スプレー
• 市販の鼻スプレー
• 併用療法鼻スプレー
• 世界のエスケタミン市場、その他のタイプのサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 血漿交換
• 静脈内免疫グロブリン（IVIG）療法
• 幹細胞療法

第7章 地域別・国別分析

• 世界のエスケタミン市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界のエスケタミン市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• エスケタミン市場：競合情勢
• エスケタミン市場：企業プロファイル
  • Cigna Corporation Overview, Products and Services, Strategy and Financial Analysis
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis
  • Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Horizon Therapeutics plc
• Hikma Pharmaceuticals plc
• Alkem Laboratories Limited
• Cerecor Inc.
• Celon Pharma S.A.
• Nortec Quimica S.A.
• XWPharma Ltd.
• Seqens Group
• SynZeal Research Pvt. Ltd.
• Arevipharma GmbH
• Sage Therapeutics Inc.
• Supriya Lifescience Ltd.
• Clexio Biosciences Ltd.
• Maithri Drugs Pvt. Ltd.
• VistaGen Therapeutics Inc.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• エスケタミン市場2029：新たな機会を提供する国
• エスケタミン市場2029：新たな機会を提供するセグメント
• エスケタミン市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Esketamine is a fast-acting anesthetic and antidepressant derived from ketamine, known for its NMDA receptor antagonist properties. It is primarily used to treat treatment-resistant depression and major depressive disorder with suicidal ideation, administered as a nasal spray under medical supervision.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The main forms of esketamine include oral medications, injections, nasal sprays, and others. Oral medications consist of pills or tablets containing esketamine, which are taken orally to treat conditions such as depression. Its indications cover major depressive disorder, chronic pain, post-traumatic stress disorder, and anxiety disorders. The patient categories include adults, pediatrics, and geriatric patients. Esketamine is applied for general anesthesia and treatment-resistant depression, and it is distributed through various channels such as hospital pharmacies, online pharmacies, and retail pharmacies.

The esketamine market research report is one of a series of new reports from The Business Research Company that provides esketamine market statistics, including the esketamine industry global market size, regional shares, competitors with the esketamine market share, detailed esketamine market segments, market trends, and opportunities, and any further data you may need to thrive in the esketamine industry. This esketamine market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The esketamine market size has grown rapidly in recent years. It will grow from$1.37 billion in 2024 to $1.52 billion in 2025 at a compound annual growth rate (CAGR) of 11.2%. The growth during the historic period can be attributed to a growing number of patients, the rising prevalence of mental health issues globally, improved awareness of the disease state, increased demand for innovative therapeutic options, and favorable regulatory approvals.

The esketamine market size is expected to see rapid growth in the next few years. It will grow to$2.31 billion in 2029 at a compound annual growth rate (CAGR) of 11.0%. The growth during the forecast period can be attributed to the rising prevalence of treatment-resistant depression, increased investment in research and development programs, demand for smart healthcare infrastructure, the growing adoption of telehealth services, and the increasing acceptance of esketamine as an effective treatment. Key trends expected during this period include partnerships between biotech companies and mental health organizations, the use of robotics in healthcare applications, personalized medicine strategies, the rise of sensor-based devices, and the potential for combination therapies.

The growing prevalence of treatment-resistant depression (TRD) is expected to drive the expansion of the esketamine market in the coming years. TRD refers to depression that does not improve despite trying at least two different antidepressant medications at appropriate doses for a sufficient duration. The rise in treatment-resistant depression is largely due to the limited effectiveness of conventional antidepressants, which leads to prolonged and recurring depressive episodes. Esketamine offers a promising solution for TRD by providing a rapid-acting mechanism that targets NMDA receptors, offering relief to patients who do not respond to traditional antidepressants. For example, in September 2023, the National Institute of Mental Health (NIMH) in the U.S. reported that approximately 30% of individuals with major depressive disorder in the U.S. are resistant to standard treatments. Consequently, the increasing incidence of treatment-resistant depression is fueling the growth of the esketamine market.

Esketamine's approval as a monotherapy for treatment-resistant depression marks a breakthrough in TRD treatment. Major companies in the esketamine market are focusing on developing advanced solutions such as monotherapy, which involves using a single drug to manage a condition, rather than combining multiple therapies. In January 2025, Johnson & Johnson, a U.S.-based pharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) had approved SPRAVATO (esketamine) as the first and only monotherapy for adults with treatment-resistant depression (TRD). Supported by clinical trial data, the approval showed that SPRAVATO could rapidly alleviate depressive symptoms, with significant improvements occurring within 24 hours. This breakthrough provides a vital option for the 30% of individuals who do not respond to traditional antidepressants, eliminating the need for additional oral medications. While SPRAVATO has a favorable safety profile, it is administered under a Risk Evaluation and Mitigation Strategy (REMS) to manage potential side effects. This milestone represents a major advancement in TRD treatment, offering renewed hope for better patient outcomes.

In April 2024, Celon Pharma S.A., a Poland-based pharmaceutical company, partnered with Tang Capital Management LLC to create Novohale Therapeutics, LLC. This collaboration is focused on advancing the development of Falkieri, an esketamine dry powder inhalation product, into global Phase 3 clinical trials for bipolar depression. Tang Capital Management LLC, a U.S.-based company specializing in life sciences and biotechnology, is working with Celon Pharma to bring this innovative treatment to market.

Major players in the esketamine market are Cigna Corporation, Pfizer Inc., Johnson & Johnson, Merck & Co. Inc., AbbVie Inc., Horizon Therapeutics plc, Hikma Pharmaceuticals plc, Alkem Laboratories Limited, Cerecor Inc., Celon Pharma S.A., Nortec Quimica S.A., XWPharma Ltd., Seqens Group, SynZeal Research Pvt. Ltd., Arevipharma GmbH, Sage Therapeutics Inc., Supriya Lifescience Ltd., Clexio Biosciences Ltd., Maithri Drugs Pvt. Ltd., and VistaGen Therapeutics Inc.

North America was the largest region in the esketamine market in 2024. The regions covered in esketamine report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the esketamine market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The esketamine market consists of sales of products including spravato, and esketamine injectable formulations. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Esketamine Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on esketamine market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for esketamine ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The esketamine market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type: Oral Medications; Injection; Nasal Spray; Other Types
• 2) By Indication: Major Depressive Disorder; Chronic Pain; Post-Traumatic Stress Disorder; Anxiety Disorders
• 3) By Patient Type: Adult Patients; Pediatric Patients; Geriatric Patients
• 4) By Application: General Anesthetic; Treatment-Resistant Depression
• 5) By Distribution Channel: Hospital Pharmacy; Online Pharmacy; Retail Pharmacy
• Subsegments:
• 1) By Oral Medications: Immediate-Release Tablets; Extended-Release Tablets; Sublingual Tablets
• 2) By Injection: Intravenous Injection; Intramuscular Injection; Subcutaneous Injection
• 3) By Nasal Spray: Prescription Nasal Spray; Over-The-Counter Nasal Spray; Combination Therapy Nasal Spray
• 4) By Other Types: Plasmapheresis; Intravenous Immunoglobulin (IVIG) Therapy; Stem Cell Therapy
• Companies Mentioned: Cigna Corporation; Pfizer Inc.; Johnson & Johnson; Merck & Co. Inc.; AbbVie Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Esketamine Market Characteristics

3. Esketamine Market Trends And Strategies

4. Esketamine Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Esketamine Growth Analysis And Strategic Analysis Framework

• 5.1. Global Esketamine PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Esketamine Market Growth Rate Analysis
• 5.4. Global Esketamine Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Esketamine Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Esketamine Total Addressable Market (TAM)

6. Esketamine Market Segmentation

• 6.1. Global Esketamine Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral Medications
• Injection
• Nasal Spray
• Other Types
• 6.2. Global Esketamine Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Major Depressive Disorder
• Chronic Pain
• Post-Traumatic Stress Disorder
• Anxiety Disorders
• 6.3. Global Esketamine Market, Segmentation By Patient Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Adult Patients
• Pediatric Patients
• Geriatric Patients
• 6.4. Global Esketamine Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• General Anesthetic
• Treatment-Resistant Depression
• 6.5. Global Esketamine Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacy
• Online Pharmacy
• Retail Pharmacy
• 6.6. Global Esketamine Market, Sub-Segmentation Of Oral Medications, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Immediate-Release Tablets
• Extended-Release Tablets
• Sublingual Tablets
• 6.7. Global Esketamine Market, Sub-Segmentation Of Injection, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Intravenous Injection
• Intramuscular Injection
• Subcutaneous Injection
• 6.8. Global Esketamine Market, Sub-Segmentation Of Nasal Spray, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Prescription Nasal Spray
• Over-The-Counter Nasal Spray
• Combination Therapy Nasal Spray
• 6.9. Global Esketamine Market, Sub-Segmentation Of Other Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Plasmapheresis
• Intravenous Immunoglobulin (IVIG) Therapy
• Stem Cell Therapy

7. Esketamine Market Regional And Country Analysis

• 7.1. Global Esketamine Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Esketamine Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Esketamine Market

• 8.1. Asia-Pacific Esketamine Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Esketamine Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Esketamine Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Esketamine Market, Segmentation By Patient Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Esketamine Market

• 9.1. China Esketamine Market Overview
• 9.2. China Esketamine Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Esketamine Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Esketamine Market, Segmentation By Patient Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Esketamine Market

• 10.1. India Esketamine Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Esketamine Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Esketamine Market, Segmentation By Patient Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Esketamine Market

• 11.1. Japan Esketamine Market Overview
• 11.2. Japan Esketamine Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Esketamine Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Esketamine Market, Segmentation By Patient Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Esketamine Market

• 12.1. Australia Esketamine Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Esketamine Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Esketamine Market, Segmentation By Patient Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Esketamine Market

• 13.1. Indonesia Esketamine Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Esketamine Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Esketamine Market, Segmentation By Patient Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Esketamine Market

• 14.1. South Korea Esketamine Market Overview
• 14.2. South Korea Esketamine Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Esketamine Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Esketamine Market, Segmentation By Patient Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Esketamine Market

• 15.1. Western Europe Esketamine Market Overview
• 15.2. Western Europe Esketamine Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Esketamine Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Esketamine Market, Segmentation By Patient Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Esketamine Market

• 16.1. UK Esketamine Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Esketamine Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Esketamine Market, Segmentation By Patient Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Esketamine Market

• 17.1. Germany Esketamine Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Esketamine Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Esketamine Market, Segmentation By Patient Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Esketamine Market

• 18.1. France Esketamine Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Esketamine Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Esketamine Market, Segmentation By Patient Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Esketamine Market

• 19.1. Italy Esketamine Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Esketamine Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Esketamine Market, Segmentation By Patient Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Esketamine Market

• 20.1. Spain Esketamine Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Esketamine Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Esketamine Market, Segmentation By Patient Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Esketamine Market

• 21.1. Eastern Europe Esketamine Market Overview
• 21.2. Eastern Europe Esketamine Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Esketamine Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Esketamine Market, Segmentation By Patient Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Esketamine Market

• 22.1. Russia Esketamine Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Esketamine Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Esketamine Market, Segmentation By Patient Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Esketamine Market

• 23.1. North America Esketamine Market Overview
• 23.2. North America Esketamine Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Esketamine Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Esketamine Market, Segmentation By Patient Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Esketamine Market

• 24.1. USA Esketamine Market Overview
• 24.2. USA Esketamine Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Esketamine Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Esketamine Market, Segmentation By Patient Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Esketamine Market

• 25.1. Canada Esketamine Market Overview
• 25.2. Canada Esketamine Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Esketamine Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Esketamine Market, Segmentation By Patient Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Esketamine Market

• 26.1. South America Esketamine Market Overview
• 26.2. South America Esketamine Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Esketamine Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Esketamine Market, Segmentation By Patient Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Esketamine Market

• 27.1. Brazil Esketamine Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Esketamine Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Esketamine Market, Segmentation By Patient Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Esketamine Market

• 28.1. Middle East Esketamine Market Overview
• 28.2. Middle East Esketamine Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Esketamine Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Esketamine Market, Segmentation By Patient Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Esketamine Market

• 29.1. Africa Esketamine Market Overview
• 29.2. Africa Esketamine Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Esketamine Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Esketamine Market, Segmentation By Patient Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Esketamine Market Competitive Landscape And Company Profiles

• 30.1. Esketamine Market Competitive Landscape
• 30.2. Esketamine Market Company Profiles
  • 30.2.1. Cigna Corporation Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Esketamine Market Other Major And Innovative Companies

• 31.1. Horizon Therapeutics plc
• 31.2. Hikma Pharmaceuticals plc
• 31.3. Alkem Laboratories Limited
• 31.4. Cerecor Inc.
• 31.5. Celon Pharma S.A.
• 31.6. Nortec Quimica S.A.
• 31.7. XWPharma Ltd.
• 31.8. Seqens Group
• 31.9. SynZeal Research Pvt. Ltd.
• 31.10. Arevipharma GmbH
• 31.11. Sage Therapeutics Inc.
• 31.12. Supriya Lifescience Ltd.
• 31.13. Clexio Biosciences Ltd.
• 31.14. Maithri Drugs Pvt. Ltd.
• 31.15. VistaGen Therapeutics Inc.

32. Global Esketamine Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Esketamine Market

34. Recent Developments In The Esketamine Market

35. Esketamine Market High Potential Countries, Segments and Strategies

• 35.1 Esketamine Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Esketamine Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Esketamine Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer
• 250617_r34845_Esketamine_GMR_2025